FDA 483 - Mixie - January 12, 2018

During an inspection of Webb Business Promotions in Saint Paul, MN, a human drug manufacturer, the FDA observed significant deficiencies in quality control unit procedures and labeling controls. The firm lacked written procedures for critical manufacturing processes and failed to follow established complaint and training procedures. Additionally, product labels were found stored without controlled access, indicating a lack of strict control over labeling operations.